Trial Indicates Azithromycin Therapy May Be Beneficial for Subset of CFS Patients; Raises Questions for Continuing Research
In a group of 99 Chronic Fatigue Syndrome patients treated experimentally for six weeks with azithromycin, a subgroup of 58 patients reported a positive decrease in overall symptom severity. Azithromycin is an antibiotic, but is also believed to possess beneficial immunomodulation (immune system affecting) abilities.
Full provisional text in Journal of Translational Medicine.
Lees het volledige artikel op ImmuneSupport